Please wait while the formulary information is being retrieved.
LIDODERM (lidocaine)
- nerve pain after herpes
5 % topical patch
- Apply 1 patch by topical route once daily (may wear up to 12Hours.)
1.8 % topical patch
- Apply 1 patch by topical route once daily (may wear up to 12Hours.)
3.5 % topical patch
- Dosage information is not available
4 % topical patch
- Dosage information is not available
5 % topical patch
- Apply 1 patch by topical route once daily (may wear up to 12Hours.)
Default screening record
- Apply 1 patch by transdermal route once daily (may wear up to 12Hours.)
- Apply 2 patches by transdermal route once daily (may wear up to 12Hours.)
- Apply 1 patch by topical route once daily (may wear up to 12Hours.)
- Apply 2 patches by topical route once daily (may wear up to 12Hours.)
- Apply 3 patches by topical route once daily (may wear up to 12Hours.)
- Apply 3 patches by transdermal route once daily (may wear up to 12Hours.)
- None
Contraindicated
- None
Severe
Moderate
- None
- Large open wound
- Methemoglobinemia
Contraindicated
- Glucose-6-phosphate dehydrogenase (g6Pd) deficiency
- Heart block
- Hemolytic anemia from pyruvate kinase and g6PD deficienc
- Sepsis
- Shock
Severe
Moderate
- Disease of liver
- Respiratory depression
- Seizure disorder
LIDODERM (lidocaine)
- nerve pain after herpes
- None
- Treatment site sequelae
More Frequent
Severe
Less Severe
- None
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acidosis
- Anaphylaxis
- Angioedema
- Bradycardia
- Bronchospastic pulmonary disease
- Cardiac arrest
- CNS depression
- Excitement
- Heart block
- Hypotension
- Hypoxia
- Urticaria
Less Severe
- None
Contraindicated
None
Severe Precaution
Lidocaine (Patch)
Rare risk of methemoglobinemia in infants age < 6 months. No safety efficacy in pediatrics. Increased sensitivity to adverse effects.
- 1 Day – 179 Days
- Rare risk of methemoglobinemia in infants age < 6 months. No safety efficacy in pediatrics. Increased sensitivity to adverse effects.
- 180 Days – 18 Years
- Rare risk of methemoglobinemia in infants age < 6 months. No safety efficacy in pediatrics. Increased sensitivity to adverse effects.
Management or Monitoring Precaution
None
Lidocaine
- Severity Level:
2
- Additional Notes: Insufficient human data available.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
Lidocaine
Amount excreted reported to be low with low infant oral bioavailability
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Excreted | Not known; no or inclusive data | Amount excreted reported to be low with low infant oral bioavailability |
Contraindicated
None
Precaution Exists
Select Anesthetics
General-May be more sensitive to CNS and cardiac adverse reactions. Consider dose reduction due to reduced clearance in the elderly.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | Y | Y | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Postherpetic neuralgia | |
| B02.22 | Postherpetic trigeminal neuralgia |
| B02.23 | Postherpetic polyneuropathy |
| 0-9 | A-Z |
|---|---|
| B02.22 | Postherpetic trigeminal neuralgia |
| B02.23 | Postherpetic polyneuropathy |
Formulary Reference Tool